ICON8 stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer.
dc.contributor.author | James, E | |
dc.contributor.author | Hook, J | |
dc.contributor.author | Stenning, S | |
dc.contributor.author | Cook, A | |
dc.contributor.author | Coyle, C | |
dc.contributor.author | Petrie, J | |
dc.contributor.author | Kaplan, R | |
dc.contributor.author | McNeish, I | |
dc.contributor.author | Perren, T | |
dc.contributor.author | Naik, R | |
dc.contributor.author | Banerjee, S | |
dc.contributor.author | Ledermann, J | |
dc.contributor.author | Clamp, Andrew R | |
dc.date.accessioned | 2017-05-02T19:56:07Z | |
dc.date.available | 2017-05-02T19:56:07Z | |
dc.date.issued | 2016-10-01 | |
dc.identifier.citation | ICON8 stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. 2016, 27(suppl 6):861P Annals of Oncology | en |
dc.identifier.issn | 0923-7534 | |
dc.identifier.issn | 1569-8041 | |
dc.identifier.doi | 10.1093/annonc/mdw374.08 | |
dc.identifier.uri | http://hdl.handle.net/10541/620312 | |
dc.language.iso | en | en |
dc.relation.url | https://academic.oup.com/annonc/article/2799597/ICON8 | en |
dc.rights | Archived with thanks to Annals of Oncology | en |
dc.title | ICON8 stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology-UCL, London | en |
dc.identifier.journal | Annals of Oncology | en |